Open House Discount Agreements for Sitagliptin and Ertugliflozin
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sitagliptin und Ertugliflozin, ATC A10BD24
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or minimum volume; actual business depends on utilisation.
Contracts will automatically cease if nationwide or regional discount agreements for the same drug are concluded under...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Non-exclusive discount agreements on pharmaceutical products containing Sitagliptin and Ertugliflozin (ATC A10BD24).
- Contracts run from 01.06.2026 to 31.05.2028.
Show full summary
This is an Open House model (not a standard procurement) by AOK Bayern for non-exclusive discount agreements on pharmaceutical products containing Sitagliptin and Ertugliflozin (ATC A10BD24) under §130c SGB V. All interested pharmaceutical companies meeting the eligibility criteria can join on identical terms. Contracts run from 01.06.2026 to 31.05.2028. No estimated value provided.
Risks
No estimated contract value or minimum volume; actual business depends on utilisation.
Contracts will automatically cease if nationwide or regional discount agreements for the same drug are concluded under...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible.
Administrative
- Must submit signed contract, signed annex listing covered medicines, and signed declaration of reliability.
- Submission: either paper (two original copies) or electronic with qualified electronic signature via DTVP portal.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Discount Agreements for Sitagliptin and Ertugliflozin
Non-exclusive discount agreements for Sitagliptin and Ertugliflozin (ATC A10BD24). Contract period 01.06.2026–31.05.2028. Joining possible anytime until 03.04.2028. No selection; all eligible pharmaceutical companies can participate.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Sitagliptin und Ertugliflozin, ATC A10BD24
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 254718-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or minimum volume; actual business depends on utilisation.
Contracts will automatically cease if nationwide or regional discount agreements for the same drug are concluded under...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications